PKS VIDEO LIBRARY
<< View complete library >>
NEWS from CONSORTIUM MEMBERS
The Wistar Institute and Cheyney University of Pennsylvania have launched a strategic collaboration uniting the nation’s first independent biomedical research institute and the nation’s first historically Black college and university (HBCU) in order to expand life science research education, training and business development opportunities in Pennsylvania.
Dr. Maureen Murphy, Ira Brind Professor and program leader of the Molecular & Cellular Oncogenesis Program of The Wistar Institute Cancer Center, has been investigating the importance of inherited mutations in the gene encoding p53 tumor suppressor protein to determine cancer susceptibility in people of African descent and people of Ashkenazi Jewish descent, for the past twenty-two years.
Creating a new drug from scratch takes many years and billions of dollars. While discovery of new molecules against SARS-CoV-2 and other emerging viruses is imperative, the world also needs solutions for COVID-19 now. This is why there has been wide interest in repurposing existing drugs, for which safety and pharmacologic profiles are already available, as a viable strategy to save critical time and resources and quickly discover potential candidate drugs to combat the pandemic.
As our state economy faces a long slog back to recovery from the COVID-19 pandemic, Wistar is poised to assist with the development of the workforce that will help enable that recovery. The Institute’s education and training programs provide just what is needed for curious, intellectually minded students to establish careers as biomedical research technicians and pursue other careers in the life sciences.
Women who deliver their first child by cesarean section (C-section) are less likely to conceive a second child than those who deliver vaginally, despite being just as likely to plan a subsequent pregnancy, according to Penn State College of Medicine researchers. They followed more than 2,000 women for three years after they delivered their first child.
Jenna Kwiecinski MedHum’20, BMS’20 was not unfamiliar with science and research when she came to USciences. Having gone to a science-based vocational high school, Kwiecinski was awarded a scholarship to USciences for her independent research and was able to hone her skills while pursuing her degrees.
Temple University Hospital’s Comprehensive Stroke Program has earned the American Heart Association/American Stroke Association’s Get With the Guidelines® Gold Plus and Target Stroke Elite Plus Quality Awards.
Temple University Hospital has treated the first five patients in the United States as part of a Phase 1 clinical trial investigating a novel immunotherapy approach for patients with COVID-19. CPI-006, developed by Corvus Pharmaceuticals, Inc., has demonstrated a potential new approach to immunotherapy of infectious diseases and cancer. Gerard J. Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University and Director of the Temple Lung Center, is the principal investigator at Temple.
For the fourth year in a row, Stephen K. Klasko, MD, MBA, has been named one of the most influential clinical executives by Modern Healthcare.This list honors those in the healthcare industry who are deemed by their peers to demonstrate exceptional leadership qualities in the field, including executive responsibility, innovation, community service and various achievements.
Women carrying twins are at higher risk for premature birth and miscarriage – those whose cervix dilates before 24 weeks are at highest risk – and yet one common treatment is not recommended for this population. A new multi-center randomized-controlled trial from Thomas Jefferson University shows that cerclage, an intervention that sutures a dilating cervix closed, can help prevent preterm birth and miscarriage. The findings could overturn existing guidelines.
If you want to stay informed about BioStrategy Parterns, subscribe here.
firstname.lastname@example.orgP.O. Box 83 Boiling Springs, PA 17007
2017, BioStrategy Partners. All rights reserved